B Braun buys McGaw for $320 million:
This article was originally published in Clinica
German company B Braun Melsungen has bought Ivax subsidiary McGaw, which makes intravenous solutions and related products, for around $320 million. B Braun will make additional payments of up to $80 million, depending on the operating results of McGaw and B Braun's US subsidiary. US company Ivax will receive royalties based on B Braun and McGaw's commercialisation of Duplex, a multi-compartment drug-delivery system designed for intravenous drugs that have limited stability after mixing.
You may also be interested in...
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, including Genmab/AbbVie’s Tepkinly, for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Singapore is taking steps to align good manufacturing practice requirements for chemical and biologic drug substance manufacturers and has rolled out a one-year transition plan for compliance.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.